MiR-107 overexpression attenuates neurotoxicity induced by 6-hydroxydopamine both in vitro and in vivo

Sun, Li; Zhang, Tingting; Xiu, Wenna; Cao, Weibiao; He, Mengfei; Sun, Wenqiang; Zhao, Weina

doi:10.1016/j.cbi.2019.108908

Cited by 22 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, studies have shown that miR-107 downregulated beta amyloid cleaving enzyme (BACE1), which generated amyloid beta peptide (Aβ) fragments by cleaving APP, leading to amyloid beta deposition promoting the development of AD [ 91 ]. However, whether the apparent down-regulation of miR-107 in AD [ 92 ] negatively up-regulates let-7 expression [ 93 ] and promotes the development of AD needs to be further verified. In addition, dysregulation of miRNAs leads to dysfunction of intracellular and extracellular biochemical processes and ultimately to neuronal cell death, which is another factor influencing AD [ 94 , 95 ].…”

Section: Let-7 and Lifespanmentioning

confidence: 99%

Let-7 as a Promising Target in Aging and Aging-Related Diseases: A Promise or a Pledge

et al. 2022

View full text Add to dashboard Cite

The abnormal regulation and expression of microRNA (miRNA) are closely related to the aging process and the occurrence and development of aging-related diseases. Lethal-7 (let-7) was discovered in Caenorhabditis elegans (C. elegans) and plays an important role in development by regulating cell fate regulators. Accumulating evidence has shown that let-7 is elevated in aging tissues and participates in multiple pathways that regulate the aging process, including affecting tissue stem cell function, body metabolism, and various aging-related diseases (ARDs). Moreover, recent studies have found that let-7 plays an important role in the senescence of B cells, suggesting that let-7 may also participate in the aging process by regulating immune function. Therefore, these studies show the diversity and complexity of let-7 expression and regulatory functions during aging. In this review, we provide a detailed overview of let-7 expression regulation as well as its role in different tissue aging and aging-related diseases, which may provide new ideas for enriching the complex expression regulation mechanism and pathobiological function of let-7 in aging and related diseases and ultimately provide help for the development of new therapeutic strategies.

show abstract

Section: Let-7 and Lifespanmentioning

confidence: 99%

Let-7 as a Promising Target in Aging and Aging-Related Diseases: A Promise or a Pledge

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similarly, the expression of miR-107 was reported to be reduced in Aβ-treated cells, and its overexpression reversed Aβ-induced injury [89] . Furthermore, the expression of miR-107 was down-regulated in dementia patients [90] and has been suggested as a potential blood-based biomarker for disease risk and progression of AD [91] . These reports support our observation that lower expression of miR-107 in NDE Oxycodone could be associated with neurodegeneration.…”

Section: Discussionmentioning

confidence: 99%

Brain cell-derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone

Kumar

Kim

et al. 2021

EBioMedicine

View full text Add to dashboard Cite

“… 171 The miR-107 was shown to have neuroprotective effects in PC12 cells and in mice after the treatment with 6-hydroxydopamine, suggesting that miR-107 plays an important role against neurotoxicity by inhibiting the expression of programmed cell death 10 (PDCD10) protein. 172 …”

Section: Potential Epigenetic Therapy For Admentioning

confidence: 99%

Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview

Štrac¹,

Konjevod²,

Šagud³

et al. 2021

PGPM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive, complex, and multifactorial neurodegenerative disorder, still without effective and stable therapeutic strategies. Currently, available medications for AD are based on symptomatic therapy, which include acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Additionally, medications such as antipsychotic drugs, antidepressants, sedative, and hypnotic agents, and mood stabilizers are used for the management of behavioral and psychological symptoms of dementia (BPSD). Clinical research has been extensively investigated treatments focusing on the hallmark pathology of AD, including the amyloid deposition, tau hyperphosphorylation, neuroinflammation, and vascular changes; however, so far without success, as all new potential drugs failed to show significant clinical benefit. The underlying heterogeneous etiology and diverse symptoms of AD suggest that a precision medicine strategy is required, which would take into account the complex genetic, epigenetic, and environmental landscape of each AD patient. The article provides a comprehensive overview of the literature on AD, the current and potential therapy of both cognitive symptoms as well as BPSD, with a special focus on gut microbiota and epigenetic modifications as new emerging drug targets. Their specific patterns could represent the basis for novel individually tailored approaches aimed to optimize precision medicine strategies for AD prevention and treatment. However, the successful application of precision medicine to AD demands a further extensive research of underlying pathological processes, as well as clinical and biological complexity of this multifactorial neurodegenerative disorder.

show abstract

MiR-107 overexpression attenuates neurotoxicity induced by 6-hydroxydopamine both in vitro and in vivo

Cited by 22 publications

References 25 publications

Let-7 as a Promising Target in Aging and Aging-Related Diseases: A Promise or a Pledge

Let-7 as a Promising Target in Aging and Aging-Related Diseases: A Promise or a Pledge

Brain cell-derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone

Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview

Contact Info

Product

Resources

About